Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Evercore ISI from $7.00 to $5.00. They now have an "outperform" rating on the stock.
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $5.00 to $4.00. They now have a "sector perform" rating on the stock.
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $5.00 to $3.00. They now have an "equal weight" rating on the stock.
Editas Medicine, Inc. (NASDAQ: EDIT) had its "neutral" rating re-affirmed by analysts at Chardan Capital.